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ABSTRACT
Cytochrome P450 (P450) enzymes play a critical role in the activation
and detoxication of many neurotoxic chemicals. Although research
has largely focused on P450-mediatedmetabolism in the liver, emerging
evidence suggests that brain P450s influence neurotoxicity by
modulating local metabolite levels. As a first step toward better
understanding the relative role of brain P450s in determining neu-
rotoxic outcome, we characterized mRNA expression of specific
P450 isoforms in the rodent brain. Adult mice (male and female)
and rats (male) were treated with vehicle, phenobarbital, or dexameth-
asone. Transcripts for CYP2B, CYP3A, CYP1A2, and the orphan
CYP4X1 and CYP2S1 were quantified in the liver, hippocampus,
cortex, and cerebellum by quantitative (real-time) polymerase chain
reaction. These P450s were all detected in the liver with the exception
of CYP4X1, which was detected in rat but not mouse liver. P450
expression profiles in the brain varied regionally. With the exception of
the hippocampus, there were no sex differences in regional brain P450
expression profiles in mice; however, there were marked species
differences. In the liver, phenobarbital induced CYP2B expression in
both species. Dexamethasone induced hepatic CYP2B and CYP3A in
mice but not rats. In contrast, brain P450s did not respond to these
classic hepatic P450 inducers. Our findings demonstrate that P450
mRNA expression in the brain varies by region, regional brain P450
profiles vary between species, and their induction varies from that of
hepatic P450s. These novel datawill be useful for designingmechanistic
studies to examine the relative role of P450-mediated brain metabolism
in neurotoxicity.
Introduction
The cytochrome P450 (P450) superfamily is a diverse group of
enzymes that catalyze the oxidative metabolism of not only endogenous
substrates but also xenobiotics, including environmental contaminants
of significant public health concern that target the nervous system,
including polychlorinated biphenyls, polybrominated diphenyl ethers,
and organophosphorus pesticides (Ariyoshi et al., 1995; Foxenberg
et al., 2007; Erratico et al., 2013; Feo et al., 2013). Biotransformation of
these compounds by P450s can result in bioactivation or detoxication,
and the balance between these activities influences the bioeffective dose,
and thus the neurotoxic outcome, following environmental exposures,
as shown in studies of humans and animal models (Foxenberg et al.,
2007; Curran et al., 2011; Kim et al., 2011; Crane et al., 2012; Khokhar
and Tyndale, 2012).
Much of the research effort to characterize P450-mediated metabo-
lism of neurotoxic compounds has focused on the liver. However, it is
now evident that P450s are expressed in a number of extrahepatic
tissues, including brain (Ding and Kaminsky, 2003; Ferguson and
Tyndale, 2011). Although total P450 content in the human and rodent
brain is generally significantly lower than that in the liver (Warner et al.,
1988; Bhamre et al., 1992; Volk et al., 1995), recent evidence from rat
studies demonstrates that P450-mediated metabolism in the brain can
contribute significantly to neurotoxicity (Khokhar and Tyndale, 2012;
Zhou et al., 2013). These data coupled with reports that P450 expression
in the brain may vary between anatomic regions of the brain (Warner
et al., 1988; Dutheil et al., 2009) have led to growing interest in the
putative role of brain P450s in determining sensitivity and response to
neurotoxic compounds via modulation of local metabolite levels (Meyer
et al., 2007; Ferguson and Tyndale, 2011; Ravindranath and Strobel,
2013).
Rodents are important models for studying the relative influence of
brain versus liver P450s on neurotoxicity; however, most of our
knowledge of P450 expression in the rodent brain is derived from
studies of whole brain homogenates, and there is a paucity of data on
regional P450 expression in the rodent brain. Additional questions
include whether the well known sex- and species-specific differences
in hepatic P450 expression extend to the brain, and whether P450s in
the brain respond to classic inducers of hepatic P450 expression. Here,
we address these questions by comparing P450 transcript levels in
three distinct regions of the rodent brain relative to expression levels in
the liver under basal conditions and following treatment with phenobar-
bital and dexamethasone, which are classic inducers of hepatic
CYP2B and CYP3A expression (reviewed by Corcos and Berthou,
2008; Greenblatt et al., 2008). We also assessed the influence of sex
and species on P450 expression profiles in the brain using the male
mouse as the reference. We studied CYP2B (mouse CYP2B10/rat
CYP2B1/2), CYP3A (mouse CYP3A11/rat CYP3A2), and CYP1A2
because these isoforms have been implicated in the metabolism of
polychlorinated biphenyls (Kania-Korwel et al., 2008, 2012; Curran
et al., 2011), polybrominated diphenyl ethers (Erratico et al., 2013;
Feo et al., 2013), and organophosphorus pesticides (Tang et al., 2001;
Foxenberg et al., 2007). Two orphan P450s, CYP4X1 and CYP2S1
(Guengerich et al., 2010), were also included in this study because
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CYP2S1 is abundantly expressed in many extrahepatic tissues
(Choudhary et al., 2003) and CYP4X1 is predominantly expressed in
the rodent brain (Bylund et al., 2002; Al-Anizy et al., 2006). The data
reported herein demonstrate brain region–specific expression of P450s
in the rodent brain that is sex- and species-dependent and generally not
altered by the classic inducers phenobarbital and dexamethasone under
conditions that significantly induce P450 expression in the liver.
Materials and Methods
Animals and Treatments. Experiments involving animals were approved
by the Institutional Animal Care and Use Committee at the University of Iowa.
Male and female C57BL/6 mice (7–8 weeks) were obtained from the Jackson
Laboratory (Bar Harbor, ME) and randomly assigned to one of four groups: 1)
phenobarbital (PB; Sigma-Aldrich, St. Louis, MO) at 102 mg/kg/day in saline
or 2) saline at 20 ml/kg/day, i.p., for 3 consecutive days; 3) dexamethasone
(DEX; Sigma-Aldrich) at 50 mg/kg/day in corn oil (CO) or 4) CO (Fisher
Scientific, Pittsburg, PA) at 10 ml/kg/day, i.p., for 4 consecutive days (Kania-
Korwel et al., 2008). Male Sprague-Dawley rats (8 weeks) were purchased
from Harlan, Inc. (Indianapolis, IN), acclimated for 1 week, then randomly
assigned to one of four groups: 1) PB at 102 mg/kg/day in saline or 2) saline at
5 ml/kg/day, i.p., for 3 consecutive days; 3) DEX at 50 mg/kg/day in CO or 4)
CO vehicle control at 5 ml/kg/day, i.p., for 4 consecutive days (Kania-Korwel
et al., 2008). Animals were euthanized 24 hours after the last treatment by CO2
asphyxiation followed by cervical dislocation. Brain regions and livers were
immediately collected on ice, weighed, placed in RNALater (Qiagen, Valencia,
CA) overnight, and then stored at280°C. The effects of treatments on liver and
total body weight are summarized in Supplemental Tables 1–3.
Assessment of mRNA Levels by Quantitative Polymerase Chain Reaction.
Tissue levels of isoform-specific P450 transcripts were quantified using a 7500
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). P450
mRNA levels were normalized to the reference gene phosphoglycerate kinase
1, and relative expression ratios between treated and vehicle control animals
were calculated by the Pfaffl method (Pfaffl, 2001) using REST 2009 software
(Qiagen, Valencia, CA). Statistical analysis was performed using the built-in
randomization techniques of REST 2009 (detailed descriptions of RNA
isolation and mRNA quantification and analyses are provided in the
Supplemental Material; Supplemental Tables 6 and 7 list primer sequences
and amplification efficiencies of primers sets, respectively).
Results and Discussion
Adult male C57BL/6 mice were used as the reference for comparison
of sex- and species-dependent differences in P450 gene expression. In
male mice, tissue-specific P450 expression patterns were similar be-
tween saline (Fig. 1A) and CO (Fig. 1C) vehicle controls. The liver
expressed CYP2B10, 3A11, 1A2, and 2S1, but not CYP4X1, which is
consistent with previous reports of brain-specific CYP4X1 expression in
Fig. 1. P450 expression profiles in the brains of adult male C57BL/6 mice. Mice were treated for 3 consecutive days with either saline (20 ml/kg/day, i.p.) (A) or an equal
volume of PB in saline (102 mg/kg/day, i.p.) (B), or for 4 consecutive days with either CO (10 ml/kg/day, i.p.) (C) or an equal volume of DEX in CO (50 mg/kg/day, i.p.)
(D). Tissues were harvested 24 hours after the last injection and P450 mRNA quantified by quantitative (real-time) polymerase chain reaction. (A and C) Baseline P450
expression determined by normalizing fractional amplification (cycle number at which fluorescence exceeds a user-defined threshold) (Ct) values for P450 transcripts in
control samples to Ct values for the reference gene [phosphoglycerate kinase 1 (Pgk1)] in the same sample. (B and D) Change in expression of the target gene in PB- or DEX-
treated animals relative to vehicle control (saline for PB and CO for DEX). All data are expressed as the mean relative expression 6 S.E. (n = 4). *P , 0.05; **P , 0.01;
***P , 0.001, significantly different from vehicle control as determined by automated randomization and bootstrapping tests (REST 2009 software). BD, below detection
limit.
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mice (Al-Anizy et al., 2006; Renaud et al., 2011). P450 expression
profiles in the brain were region-specific: all five P450 isoforms were
expressed in the hippocampus; the cerebellum expressed transcripts for
all but CYP1A2, and the cortex expressed only CYP2S1 and CYP4X1
mRNA (Fig. 1, A and C). Treatment with either PB or DEX induced
P450 expression in the liver (Fig. 1, B and D; see also Supplemental
Fig. 2. P450 expression profiles in the brains of adult female C57BL/6 mice. Mice were treated for 3 consecutive days with either saline (20 ml/kg/day, i.p.) (A) or an equal
volume of PB in saline (102 mg/kg/dat, i.p.) (B), or for 4 consecutive days with either CO (10 ml/kg/day, i.p.) (C) or an equal volume of DEX in CO (50 mg/kg/day, i.p.) (D).
Tissues were harvested 24 hours after the last injection and P450 mRNA measured by quantitative (real-time) polymerase chain reaction. (A and C) Baseline P450 expression
determined by normalizing fractional amplification (Ct) values for P450 transcripts in control samples to Ct values for phosphoglycerate kinase 1 (Pgk1) in the same sample.
(B and D) Change in expression of the target gene in PB- or DEX-treated animals relative to vehicle control (saline for PB and CO for DEX). (E) Ct values for hippocampal
CYP2B10, CYP3A11, and CYP1A2 in the PB group (a,b,c) and the DEX group (d,e,f) of individual mice. Data in (A–D) are expressed as the mean 6 S.E. (n = 4–5).
*P , 0.05; **P , 0.01; ***P , 0.001, significantly different from vehicle controls as determined using the REST 2009 software. BD, below detection limit.
Cytochrome P450 mRNA Expression in Rodent Brain 241
Tables 4 and 5): hepatic CYP2B10 was induced by PB [mean of 35.1;
68% confidence interval (CI): 14.8–75.7] and by DEX (mean of 58.8;
68% CI: 30.6–137.5). DEX also induced hepatic CYP3A11 (mean of
6.9; 68% CI: 3.8–12.2). However, neither PB nor DEX induced
expression of any target P450 in the hippocampus, cerebellum, or
cortex (Fig. 1, B and D).
To explore the influence of sex, we measured P450 transcript levels
in female C57BL/6 mice. Baseline P450 expression in the liver and
cortex was similar between the saline (Fig. 2A) and CO (Fig. 2C)
vehicle controls, and comparable to profiles observed in male vehicle
controls (Fig. 1, A and C). Similar to males, all five P450 isoforms
were expressed in the hippocampus of CO-treated females (Fig. 2C);
however, in contrast to males, only CYP4X1 and CYP2S1 were
detected in the hippocampus of saline-treated females (Fig. 2A). CO
has been previously reported to influence P450 expression in the rat
liver (Yoo et al., 1990), but it is unclear whether our findings reflect
CO-mediated increase in P450 levels in the female mouse hippocam-
pus. Although differences between saline- and CO-treated female mice
could be experimental artifact, this seems unlikely because hippo-
campal expression levels of CYP4X1 and CYP2S1 were comparable
between the two vehicle treatments and between sexes.
As observed in male mice, PB induced hepatic CYP2B10 ex-
pression in female mice by a mean factor of 13.2 (68% CI: 6.6–23.7),
whereas DEX induced hepatic expression of CYP2B10 and CYP3A11
by 48.6 (68% CI: 30.6–91.1) and 8.21 (68% CI: 5.6–11.0), res-
pectively (Fig. 2, B and D). Also consistent with male mice, PB or
DEX did not change P450 expression in the cortex of female mice.
Similarly, DEX had no effect on P450 expression in the female
hippocampus. However, in contrast to males, PB significantly induced
expression of CYP2B10 (mean of 164; 68% CI: 56–529), CYP3A11
(mean of 279; 68% CI: 113–724), and CYP1A2 (mean of 36; 68% CI:
14–94) in the hippocampus of females relative to saline vehicle
controls (Fig. 2B). Data for these three transcripts are shown for in-
dividual female mice in Fig. 2E.
To investigate species-dependent differences, P450 transcripts were
quantified in male rats. Tissue-specific P450 expression profiles were
similar between saline (Fig. 3A) and CO (Fig. 3C) vehicle controls,
but varied from those observed in the comparable male mouse treatment
groups (Fig. 1, A and C). Specifically, in the male rat, all five P450
isoforms of interest were expressed in the liver, including CYP4X1
(Fig. 3, A and C). Also in contrast to male mice, rat brain expressed
CYP3A2, CYP4X1, and CYP2S1 in the hippocampus, cortex, and
cerebellum, but neither CYP2B1/2 nor CYP1A2 was detected in any
of these three brain regions (Fig. 3, A and C). These findings are
consistent with previous studies of regional P450 expression in rat
brain, with the exception that others have reported the presence of
Fig. 3. P450 expression profiles in the brain of adult male Sprague-Dawley rats. Rats were treated for 3 consecutive days with either saline (5 ml/kg/day, i.p.) (A) or an equal
volume of PB in saline (102 mg/kg/day, i.p.) (B), or for 4 consecutive days with either CO (5 ml/kg/day, i.p.) (C) or an equal volume of DEX in CO (50 mg/kg/day, i.p.) (D).
Tissues were harvested 24 hours after the last injection and P450 mRNA quantified by quantitative (real-time) polymerase chain reaction. (A and C) Baseline P450
expression determined by normalizing fractional amplification (Ct) values for CYP transcripts in vehicle control tissues to Ct values for phosphoglycerate kinase 1 (Pgk1) in
the same sample. (B and D) Change in expression of the target gene in PB- or DEX-treated animals relative to control (saline for PB and CO for DEX). Data are expressed as
the mean6 S.E. (n = 3 except for PB-treated cerebellum, in which n = 2). *P, 0.05; **P , 0.01; ***P , 0.001, significantly different from vehicle controls as determined
by automated randomization and bootstrapping tests (REST 2009 software). BD, below detection limit; NA, not available because of low amplification efficiency.
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CYP2B in rat brain (Schilter and Omiecinski, 1993). Similar to male
mice, PB (Fig. 3B) and DEX (Fig. 3D) induced P450 expression in the
male rat liver but not in any of the three brain regions. However, the
profile of hepatic P450 isoforms induced by these chemical treatments
showed species variation. In the rat, PB induced the expression of not
only CYP2B1/2 (by a mean factor of 504; 68% CI: 298–1044) but
also CYP3A2 (by a mean factor of 3.4; 68% CI: 1.8–7.1). Surprisingly,
DEX did not significantly alter hepatic CYP2B1/2 or CYP3A2 ex-
pression, but instead significantly upregulated CYP4X1 expression
(by a mean factor of 6.5; 68% CI: 1.5–78.8). Although the latter is
a novel finding, given the low fold-induction and the lack of protein
expression data, the functional significance of this upregulation is not
clear.
To further investigate sex- and species-specific differences in hepatic
P450 induction, we compared relative CYP2B and CYP3A induction
in the liver of male versus female mice and between male mice and
male rats. We found no significant sex differences in P450 induction
patterns in mice (Fig. 4A). Conversely, there were significant differ-
ences in hepatic P450 induction between mice and rats (Fig. 4B).
Hepatic CYP2B expression was induced by DEX in mice but not rats,
and CYP3A expression was induced by PB in mice but not rats and by
DEX in rats but not mice.
In summary, these data suggest that P450 mRNA expression in the
brain 1) differs significantly from hepatic P450 transcript profiles in
rodent models; 2) varies between brain regions; 3) exhibits subtle sex-
dependent differences in the C57BL/6 mouse, but significant species-
specific differences between mouse and rat; and 4) with the possible
exception of P450s in the hippocampus of the female mouse, is not
induced by PB or DEX regimens that induce hepatic orthologs. With
respect to the last finding, previous studies of whole brain homogenates
have reported either no P450 induction by these classic inducers (Schilter
et al., 2000; Hedlund et al., 2001; Upadhya et al., 2002; Woodland et al.,
2008) or CYP2B induction by PB (Schilter and Omiecinski, 1993;
Schilter et al., 2000; Upadhya et al., 2002). Discrepancies between studies
likely reflect differences in dose and duration of treatment, species and/or
strain, whole brain versus isolated brain regions, primer specificity, and
methods of mRNA quantification. Although it will be necessary to
confirm protein levels and activity of these P450 isoforms to
corroborate the significance of these findings, emerging evidence
of brain P450-mediated xenobiotic activation strongly suggests that
differences in regional expression of brain P450s may be an important
mechanism contributing to region-selective neurotoxicity (Spencer and
Lein, 2013).
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Detailed Materials and Methods 
 
Total RNA extraction and reverse transcription   
Following the manufacturer’s instructions, total RNA was extracted from liver, 
hippocampus and cortex samples using RNeasy (Qiagen, Valencia, CA), and from cerebellum 
samples using Trizol (Invitrogen, Carlsbad, CA). Following digestion of total RNA with 100 U of 
DNase I (Invitrogen), 1 µg of total RNA per sample was mixed with 200 U of Superscript III 
reverse transcriptase and 50 ng/µl of random hexamer primers and reverse transcribed to cDNA 
using the Superscript III First Strand Synthesis kit (Invitrogen) according to the manufacturer’s 
protocol. The OD260nm/OD280nm of resultant cDNA was confirmed to be >1.8. 
 
Quantitative polymerase chain reaction (qPCR)  
Primer and probe sets for specific CYP isoforms (Table S6) were designed in-house 
using PrimerBlast from NCBI (Bethesda, MD) and PrimerQuest software (IDT, Coralville, IA). 
Separate primer and probe sets were designed for mouse versus rat CYP genes. Specificity of 
the primers and probes for each gene was confirmed by BLASTN searches conducted against 
nucleotide collection databases for Mus musculus and Rattus norvegicus. CYP isoform-specific 
primer and probe sets were synthesized by IDT, which was also the source of a commercially 
available primer and probe set for the reference gene phosphoglycerate kinase 1 (Pgk1). Pgk1 
has previously been reported to be a stable reference gene for qPCR analyses of brain samples 
(Santos and Duarte, 2008), and we similarly found stable Pgk1 expression across all species, 
tissues and tissue regions, irrespective of treatment. All fluorescent probes contained a ZEN 
internal quencher (IDT) to eliminate background fluorescence.   
qPCR was performed using a 7500 Fast Real-Time PCR System (Applied Biosystems, 
Foster City, CA) using the Taqman Universal PCR Master Mix (Life Sciences, Grand Island, NY) 
according to the manufacturer’s instructions. Thermal cycling conditions consisted of an initial 
annealing step at 50oC for 2 min, followed by a denaturation step at 95oC for 10 min and 40 
cycles at 95oC for 15 sec and 60oC for 1 min.  After synthesis, PCR products were subjected to 
1% agarose gel electrophoresis to confirm that products were of the expected band size.  No-
template and no-enzyme controls were run with each assay and confirmed to produce negligible 
signal (> 39 Ct value where Ct is defined as the fractional amplification cycle number at which 
fluorescence exceeds a defined threshold). Samples from saline vehicle controls were used to 
construct dilution curves for each CYP transcript and estimate amplification efficiencies for each 
tissue from male and female mice and male rats. The amplification efficiency for each gene was 
calculated using the Pfaffl equation (Pfaffl, 2001):  E = 10-1/slope -1.   
 
Analysis of qPCR data  
Analysis of amplification results was performed using the 7500 Fast System SDS 
software (Applied Biosystems) to obtain Ct values (Pfaffl et al., 2002). For all samples in the 
vehicle control groups (saline and corn oil treatments), the Ct value obtained for each CYP 
transcript was normalized to the Ct value for the reference gene (Pgk1) within the same sample. 
Since high Ct values correspond to low transcript levels, reciprocal Ct values for each gene 
were normalized to the reciprocal Ct values for Pgk1 in samples from vehicle controls to assess 
baseline CYP transcript expression across tissues. Two-way ANOVA with post hoc Bonferroni 
test was used identify significant vehicle effects on transcript expression levels.  
CYP expression levels in animals treated with phenobarbital (PB) or dexamethasone 
(DEX) were compared to those of animals treated with the appropriate vehicle, which was saline 
for PB and corn oil for DEX.  Relative differences in gene expression between experimental 
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groups are often determined using the delta-delta-Ct (ddCt) algorithm (Livak and Schmittgen, 
2001). However, this algorithm assumes that the amplification efficiencies of the target gene 
and the reference gene are identical. To assess whether this condition was met in our study, we 
first constructed dilution curves and calculated the amplification efficiency for each gene in each 
tissue of interest harvested from saline-treated animals. As shown in Table S1, amplification 
efficiencies were different between the CYP genes and our reference gene; therefore, we could 
not use the ddCt algorithm.  Instead,  expression levels in PB- or DEX-treated animals relative 
to the appropriate vehicle control animals (saline for PB and CO for DEX) were analyzed using 
the REST2009 software (Qiagen), which employs  an amplification efficiency corrected 
calculation model based on multiple samples according to the following formula (Pfaffl, 2001; 
Pfaffl et al., 2002):  
 
Relative expression = (concentration of CYP target gene) / (concentration of Pgk1) 
 
In this formula, concentration = efficiency∆Ct. The ∆Ct value for each gene was determined by 
subtracting the average Ct value of the gene of interest in the control sample from the average 
Ct value of the same gene in the treated sample. The REST2009 software determines the 
statistical significance of calculated expression ratios using randomization algorithms (random 
pairing of controls and samples from the gene of interest and the reference gene, and 
calculation of their expression ratio). 
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Table S1: Treatment effects on body and liver weights of male micea 
Treatment Final 
weight [g] 
Body weight 
change 
Liver weight    
[g] 
Liver-to-body 
weight ratio 
Phenobarbital (n=4) 21.9 ± 1.7 2.1 ± 3.4 1.4 ± 0.1 6.2 ± 0.5* 
Saline (n=5) 22.9 ± 2.3 0.1 ± 0.4 1.1 ± 0.1 4.8 ± 0.3 
Dexamethasone (n=4) 23.1 ± 1.5 -0.6 ± 0.5 1.9 ± 0.4*# 8.3 ± 1.1*# 
Corn oil (n=5) 24.3 ± 0.9 -0.2 ± 0.3 1.2 ± 0.1 4.8 ± 0.1 
aValues represent the means ± standard deviation. *Significantly different from vehicle control 
(saline for phenobarbital; corn oil for dexamethasone) at p < 0.5; #significantly different from 
phenobarbital at p < 0.5 (paired Student’s t-test, SAS version 9.3).  
 
 
Table S2: Treatment effects on body and liver weights of the female micea 
Treatment Final 
weight [g] 
Body weight 
change 
Liver weight    
[g] 
Liver-to-body 
weight ratio 
Phenobarbital (n=4) 18.3 ± 1.3 -1.8 ± 1.0 1.8 ± 0.2* 9.9 ± 1.1* 
Saline solution (n=5) 17.0 ± 1.1 -0.7 ± 0.4 1.3 ± 0.2 7.4 ± 1.2 
Dexamethasone (n=5) 18.8 ± 0.9 0.7 ± 0.7# 1.6 ± 0.3* 8.7 ± 1.2* 
Corn oil (n=4) 18.0 ± 0.4 -0.1 ± 0.1 1.1 ± 0.1 6.0 ± 0.5 
aValues represent means ± standard deviation. *Significantly different from vehicle control at p < 
0.5 (saline for phenobarbital; corn oil for dexamethasone); #significantly different from 
phenobarbital at p < 0.5 (paired Student’s t-test, SAS version 9.3).  
 
 
Table S3: Treatment effects on body and liver weights of male ratsa 
Treatment Final  
weight [g] 
Body weight 
change 
Liver weight    
[g] 
Liver-to-body weight 
ratio 
Phenobarbital (n=3) 314.0 ± 11.4 7.3 ± 7.6 15.4 ± 1.5 4.9 ± 0.3* 
Saline (n=5) 306.6  ± 5.9 3.2 ± 3.5 12.8 ± 0.5 4.2 ± 0.1 
Dexamethasone (n=5) 238.0 ± 11.0*# -57.0 ± 4.0*# 16.0 ± 1.3*# 6.7 ± 0.3*# 
Corn oil (n=5) 298.8  ± 6.2 1.8 ± 1.9 12.7 ± 1.0 4.3 ± 0.3 
aValues represent means ± standard deviation. *Significantly different from vehicle control at p < 
0.5 (saline for phenobarbital; corn oil for dexamethasone); #significantly different from 
phenobarbital at p < 0.5 (paired Student’s t-test, SAS version 9.3).
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Table S4: Fold-change in hepatic cytochrome P450 enzyme mRNA in phenobarbital-induced animals relative to saline vehicle 
controls 
 Male C57Bl/6 mice Female C57Bl/6mice Male Sprague Dawley rats 
CYP enzyme Relative 
expression 
Standard 
error 
95% 
confidence 
interval 
Relative 
expression 
Standard 
error 
95% 
confidence 
interval 
Relative 
expression 
Standard 
error 
95% 
confidence 
interval 
Murine CYP2B10 
(rat CYP2B1/2) 
35.1* 14.8-
75.7 
9.6-134 13.2* 6.6-23.7 4.5-31.0 504* 298-
1044 
156-1290 
Murine  
CYP3A11 (rat 
CYP3A2) 
1.5 0.7-3.4 0.4-5.1 1.5 1.0-2.2 0.8-2.9 3.4 1.8-7.1 1.2-11.3 
CYP1A2 0.7 0.3-1.6 0.2-3.4 0.5 0.0-8.3 0.0-18.5 0.6 0.3-1.8 0.1-2.4 
CYP4X1       0.0 0.0-0.2 0.0-0.4 
CYP2S1 0.8 0.5-1.5 –0.2-2.0 0.7 0.2-1.6 0.1-5.9 0.1 0.0-0.4 0.0-0.8 
*Indicates statistically significant change (upregulation) of gene expression in phenobarbital-induced animals compared to expression 
in saline vehicle animals (p<0.05). The relative expression is calculated as the ratio of the concentration of the target gene compared 
to the concentration of the reference gene (Pgk1). Concentrations, relative expression, standard error and 95% confidence intervals 
were calculated using the REST2009 software (Qiagen, Valencia, CA), which incorporates Ct and efficiency values determined by 
qPCR analysis. 
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Table S5: Fold-change in hepatic cytochrome P450 enzyme mRNA in dexamethasone-induced animals relative to corn oil vehicle 
controls 
 Male C57Bl/6 mice Female C57Bl/6mice Male Sprague Dawley rats 
CYP enzyme Relative 
expression 
SE 95% 
confidence 
interval 
Relative 
expression 
SE 95% 
confidence 
interval 
Relative 
expression 
SE 95% 
confidence 
interval 
Murine CYP2B10 
(rat CYP2B1/2) 
58.8* 30.6-
137 
15.5-205 48.6* 30.6-
91.0 
18.8-115 15.7 1.7-
158 
0.7-302 
Murine  CYP3A11 
(rat CYP3A2) 
6.9* 3.8-
12.2 
2.5-18.8 8.2 5.6-
11.0 
4.8-15.3 2.8 0.8-
12.6 
0.5-24.5 
CYP1A2 0.3 0.2-
0.5 
0.1-0.6 0.5 0.2-
0.9 
0.2-1.7 1.2 0.3-
5.2 
0.1-14.2 
CYP4X1       6.5* 1.5-
48.8 
1.2-95.6 
CYP2S1 1.0 0.4-
1.8 
0.3-2.0 0.7 0.3-
1.6 
0.2-2.1 13.2 3.0-
60.4 
2.0-195 
*Indicates statistically significant change (upregulation) of gene expression in dexamethasone-induced animals compared to 
expression in corn oil-treated animals (p<0.05). The relative expression is calculated as the ratio of the concentration of the target 
gene compared to the concentration of the reference gene (Pgk1). Concentrations, relative expression, standard error and 95% 
confidence intervals were calculated using the REST2009 software (Qiagen, Valencia, CA), which incorporates Ct and amplification 
efficiency values determined by qPCR analysis. 
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Table S6. CYP-specific primer set sequences  
Human CYP 
isoform Mouse orthologue Rat orthologue 
CYP2B6 CYP2B10 CYP2B1/2 
 
Forward primer 5’CCAAATCTCCAGGGCTCCAAGGC3’ Forward primer 5’ CAACCCTTGATGACCGCAGT3’ 
 Reverse primer 5’TGCGGACTTGGGCTATTGGGAGG3’ Reverse primer 5’ TGGAGAGCTGAACTCAGGATGGG3’ 
CYP3A4 CYP3A11 CYP3A2 
 
Forward primer 5’ACAAGCAGGGATGGACCTGGTT3’ Forward primer 5’ AATGGAGCCTGACTTTCCCTCAAG3 
 Reverse primer 5’CCCATATCGGTAGAGGAGCACCA3’ Reverse primer 5’GCATCAAGAGCAGTCAATTAAGTCCCAG3’ 
CYP1A2 CYP1A2 CYP1A2 
 Forward primer 5’CCAGCCCCTGCCCTTCAGTGGTA3’ Forward primer 5’ ATGAAGCCCAGAACCTGTGAAC3’ 
 
Reverse primer 5’TGGGAACCTGGGTCCTTGAGGC3’ Reverse primer 5’ GTATGGGTTTGCAGGGAACAGT3’ 
CYP4X1 CYP4X1 CYP4X1 
 Forward primer 5’CACCCTTGTGCCTTCCCCTGC3’ Forward primer 5’ AAACGGCACCTATGAGTCTTATG3’ 
 
Reverse primer 
5’CCTCGTCCAATGCATGGAGTCAGG3
’ Reverse primer 5’ TTGCCTAACTCCTGGAAGCA3’ 
CYP2S1 CYP2S1 CYP2S1 
 Forward primer 5’TCGGGGCTTTTGCGGCTAAGT3’ Forward primer 5’ AGGACGTCCATTCAACCCTTCCAT3’ 
 
Reverse primer 5’CAACCAGGACCACCACGCGG3’ Reverse primer 5’ TCATAGGGCAAACGGATGCCAAAG 3’ 
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Table S7. Amplification efficiencya of Pgk1 (reference gene) and CYP genes 
 
Pgk1 CYP2B10 CYP3A11 CYP1A2 CYP4X1 CYP2S1 
 R2 Eb R2 E R2 E R2 E R2 E R2 E 
Male C57BL/6 mice 
Liver 0.997 110% 0.997 64% 0.991 80% 0.974 89%  NDc  0.953 113% 
Hippocampus 0.986 109% 0.96 104% 0.952 80% 0.940 98% 0.983 90% 0.988 113% 
Cortex 0.975 112%  ND   ND   ND  0.952 59% 0.987 102% 
Cerebellum 0.932 113% 0.975 96% 0.982 67%  ND  0.983 93% 0.991 104% 
Female C57BL/6 miced 
Liver 0.988 115% 0.982 100% 0.987 84% 0.995 102% ND  0.985 115% 
Hippocampus 0.998 95% NDe  NDe  NDe  0.970 82% 0.976 82% 
Cortex 0.997 77% ND  ND  ND  0.993 77% 0.994 81% 
Male Sprague Dawley rats 
Liver 0.954 89% 0.992 96.50% 0.998 96.60% 0.995 94% 0.985 96% 0.983 103% 
Hippocampus 0.969 89% ND  0.96 87% ND  0.987 90% 0.95 105% 
Cortex 0.941 104% ND  0.959 93.60% 0.991 95% 0.987 102% 0.997 102% 
Cerebellum 0.972 111% ND  ND  ND  0.971 94% 0.975 98% 
aAmplification efficiency was determined from tissues of saline-treated animals; bE = efficiency; cND = not detected; dsamples from 
cerebellum of female mice were not used due to the low quality of total RNA extracted from these tissues; ein the absence of 
expression in the saline-treated animals, upregulation of this CYP was calculated using the amplification efficiency for the same CYP 
from male mice. 
